Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,25245190,area under the curve₀₋₂₄,"In the treatment group, compared to the control group, an increase in area under the curve₀₋₂₄ (16.69 h*ng/mL vs. 25.20 h*ng/mL; p<.05) and maximum serum concentration (2.09 ng/mL vs. 3.19 ng/mL; p<.05), decrease (25%-40%) in apparent volume of distribution and apparent clearance, and unaltered half-life were observed.",Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25245190/),[h·ng] / [ml],16.69,513,DB00717,Norethindrone
,25245190,area under the curve₀₋₂₄,"In the treatment group, compared to the control group, an increase in area under the curve₀₋₂₄ (16.69 h*ng/mL vs. 25.20 h*ng/mL; p<.05) and maximum serum concentration (2.09 ng/mL vs. 3.19 ng/mL; p<.05), decrease (25%-40%) in apparent volume of distribution and apparent clearance, and unaltered half-life were observed.",Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25245190/),[h·ng] / [ml],25.20,514,DB00717,Norethindrone
,25245190,maximum serum concentration,"In the treatment group, compared to the control group, an increase in area under the curve₀₋₂₄ (16.69 h*ng/mL vs. 25.20 h*ng/mL; p<.05) and maximum serum concentration (2.09 ng/mL vs. 3.19 ng/mL; p<.05), decrease (25%-40%) in apparent volume of distribution and apparent clearance, and unaltered half-life were observed.",Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25245190/),[ng] / [ml],2.09,515,DB00717,Norethindrone
,25245190,maximum serum concentration,"In the treatment group, compared to the control group, an increase in area under the curve₀₋₂₄ (16.69 h*ng/mL vs. 25.20 h*ng/mL; p<.05) and maximum serum concentration (2.09 ng/mL vs. 3.19 ng/mL; p<.05), decrease (25%-40%) in apparent volume of distribution and apparent clearance, and unaltered half-life were observed.",Increased exposure of norethindrone in HIV+ women treated with ritonavir-boosted atazanavir therapy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25245190/),[ng] / [ml],3.19,516,DB00717,Norethindrone
,10496299,absolute bioavailability,It is rapidly absorbed with an absolute bioavailability of between 40 and 50%.,Clinical pharmacokinetics of troglitazone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),%,40 and 50,2272,DB00717,Norethindrone
,10496299,elimination half-life,"The mean elimination half-life ranges from 7.6 to 24 hours, which facilitates a once daily administration regimen.",Clinical pharmacokinetics of troglitazone. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/10496299/),h,7.6 to 24,2273,DB00717,Norethindrone
,9262934,relative bioavailability,"The estimates of relative bioavailability ranged from 13 to 51% in rabbits, monkeys, and women.","Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262934/),%,13 to 51,8428,DB00717,Norethindrone
,9262934,elimination half-life,The elimination half-life was 5-10 days.,"Pharmacokinetics of orally administered norethisterone enanthate in rabbit, monkey, and women. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9262934/),d,5-10,8429,DB00717,Norethindrone
,2766722,C.V.s,"Intra-individual C.V.s were 41% and 42%, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,41,11325,DB00717,Norethindrone
,2766722,C.V.s,"Intra-individual C.V.s were 41% and 42%, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,42,11326,DB00717,Norethindrone
,2766722,AUC,"For norethindrone, the AUC was larger with the 1 + 50 formulations than with the 1 + 35 group (87.9 vs. 72.8 pg hr/ml).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),[h·pg] / [ml],87.9,11327,DB00717,Norethindrone
,2766722,AUC,"For norethindrone, the AUC was larger with the 1 + 50 formulations than with the 1 + 35 group (87.9 vs. 72.8 pg hr/ml).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),[h·pg] / [ml],72.8,11328,DB00717,Norethindrone
,2766722,Cmax,"Additionally, the Cmax values were larger for the 1/50 group (17.7 vs. 14.0).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),,17.7,11329,DB00717,Norethindrone
,2766722,Cmax,"Additionally, the Cmax values were larger for the 1/50 group (17.7 vs. 14.0).","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),,14.0,11330,DB00717,Norethindrone
,2766722,C.V.,The inter-individual C.V. averaged 56% for both dosage groups.,"Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,56,11331,DB00717,Norethindrone
,2766722,C.V.s,"The intra-individual C.V.s were 17% and 46% for the 1 + 35 and 1 + 50 groups, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,17,11332,DB00717,Norethindrone
,2766722,C.V.s,"The intra-individual C.V.s were 17% and 46% for the 1 + 35 and 1 + 50 groups, respectively.","Pharmacokinetics of three bioequivalent norethindrone/mestranol-50 micrograms and three norethindrone/ethinyl estradiol-35 micrograms OC formulations: are ""low-dose"" pills really lower? ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2766722/),%,46,11333,DB00717,Norethindrone
,1776487,times to reach peak levels,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,4.0,14512,DB00717,Norethindrone
,1776487,times to reach peak levels,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,5.4,14513,DB00717,Norethindrone
,1776487,peak values,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),ng,5.0,14514,DB00717,Norethindrone
,1776487,peak values,"Following a single im NET-EN 200 mg, the times to reach peak levels of NET-EN and NET were 4.0 +/- 2.8 d and 5.4 +/- 2.0 d, and their peak values were 5.0 +/- 1.8 and 12.6 +/- 0.9 ng.",[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),ng,12.6,14515,DB00717,Norethindrone
,1776487,apparent elimination T1/2,Mean apparent elimination T1/2 were 14.8 +/- 3.8 d for and 11.4 +/- 5.7 d for NET-EN.,[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,14.8,14516,DB00717,Norethindrone
,1776487,apparent elimination T1/2,Mean apparent elimination T1/2 were 14.8 +/- 3.8 d for and 11.4 +/- 5.7 d for NET-EN.,[Pharmacokinetics of norethindrone enanthate 200 mg after intramuscular injection in 25 Chinese women]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1776487/),d,11.4,14517,DB00717,Norethindrone
,1887788,absolute bioavailability,The absolute bioavailability for NETO and NET were found to be 64.46 +/- 34.60% and 35.02 +/- 26.49% respectively.,[Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887788/),%,64.46,15124,DB00717,Norethindrone
,1887788,absolute bioavailability,The absolute bioavailability for NETO and NET were found to be 64.46 +/- 34.60% and 35.02 +/- 26.49% respectively.,[Pharmacokinetics of norethindrone-3-oxime and norethindrone in rhesus monkeys]. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1887788/),%,35.02,15125,DB00717,Norethindrone
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],37.8,19017,DB00717,Norethindrone
,37091,A.U.C.,Rifampicin caused a significant reduction in the A.U.C. of a single dose of 1 mg norethisterone from 37.8 +/- 13.1 to 21.9 +/- 5.9 ng/ml X h (p less than 0.01).,The effect of rifampicin on norethisterone pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),[ng] / [h·ml],21.9,19018,DB00717,Norethindrone
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,6.2,19019,DB00717,Norethindrone
,37091,half life (beta-phase),The plasma norethisterone half life (beta-phase) was also reduced from 6.2 +/- 1.7 to 3.2 +/- 1.0 h (p less than 0.0025).,The effect of rifampicin on norethisterone pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/37091/),h,3.2,19020,DB00717,Norethindrone
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],116-160,24508,DB00717,Norethindrone
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],55-78,24509,DB00717,Norethindrone
,3089683,Peak plasma concentrations,"Peak plasma concentrations of EE2 ranged between 116-160 pg ml-1 for Ovral, 55-78 pg ml-1 for Norminest and 30-70 pg ml-1 for Nordette.","Pharmacokinetics of oral contraceptive steroids in Egyptian women: studies with Ovral, Nordette and Norminest. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3089683/),[pg] / [ml],30-70,24510,DB00717,Norethindrone
,7285572,half-life of elimination,"Calculation of the half-lives for absorption, distribution and elimination showed wide variations between subjects, the half-life of elimination varying from 2.5 h to more than 30 h.",Pharmacokinetics of ethynyloestradiol in women for different populations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285572/),h,2.5,26692,DB00717,Norethindrone
more,7285572,half-life of elimination,"Calculation of the half-lives for absorption, distribution and elimination showed wide variations between subjects, the half-life of elimination varying from 2.5 h to more than 30 h.",Pharmacokinetics of ethynyloestradiol in women for different populations. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7285572/),h,30,26693,DB00717,Norethindrone
,23064958,steady-state plasma concentration,"The mean ± SD vismodegib steady-state plasma concentration (Day 8, N = 51) was 20.6 ± 9.72 μM (range 7.93-62.4 μM).",Co-administration of vismodegib with rosiglitazone or combined oral contraceptive in patients with locally advanced or metastatic solid tumors: a pharmacokinetic assessment of drug-drug interaction potential. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23064958/),μM,20.6,30393,DB00717,Norethindrone
,15244497,area under the plasma concentration-time curve from zero to 24 hours (AUC24),"In Study I (tazarotene 1.1 mg), the area under the plasma concentration-time curve from zero to 24 hours (AUC24) and the peak concentration in plasma (Cmax) for tazarotenic acid were 121 +/- 27 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,121,38951,DB00717,Norethindrone
,15244497,AUC24,"In Study II (tazarotene 6 mg), AUC24 and Cmax for tazarotenic acid were 379 +/- 78 microg.",Tazarotene does not affect the pharmacokinetics and efficacy of a norethindrone/ethinylestradiol oral contraceptive. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15244497/),μg,379,38952,DB00717,Norethindrone
,18294327,AUC(tau),"Voriconazole geometric mean AUC(tau) and C(max) increased 46% (12 682-18 495 ng h ml(-1); 90% confidence interval [CI] 32, 61) and 14% (2485-2840 ng ml(-1); 90% CI 3, 27), respectively, when co-administered with oral contraceptive vs. voriconazole alone.",Pharmacokinetics and tolerability of voriconazole and a combination oral contraceptive co-administered in healthy female subjects. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18294327/),[h·ng] / [ml],12,43795,DB00717,Norethindrone
,24161160,AUC24h,"Norethindrone pharmacokinetics were unaffected by rilpivirine (AUC24h: 0.89, 0.84 - 0.94; Cmin: 0.99, 0.90 - 1.08; Cmax: 0.94, 0.83 - 1.06).",Lack of an effect of rilpivirine on the pharmacokinetics of ethinylestradiol and norethindrone in healthy volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24161160/),,0,49051,DB00717,Norethindrone
,24602553,peak time (acrophase),"However, in postmenopausal women the melatonin peak time (acrophase) was delayed by 2.4h (2 h 21 min) on average after 6 months with HT vs. placebo (p<0.05).","The effect of hormone therapy on serum melatonin concentrations in premenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24602553/),h,2.4,55821,DB00717,Norethindrone
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,14.91,61629,DB00717,Norethindrone
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),,13.56,61630,DB00717,Norethindrone
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,15.13,61631,DB00717,Norethindrone
,3956050,half-life,"In the 6 women studied prospectively the mean salivary antipyrine half-life was 14.91 +/- 1.5 hours (SEM) before administering the injection, and 13.56 +/- 0.73 at 2 weeks, 15.13 +/- 1.86 at 8 weeks and 15.21 +/- 2.46 hours at 12 weeks after the injection.",Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,15.21,61632,DB00717,Norethindrone
,3956050,half-life,The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users.,Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,14.21,61633,DB00717,Norethindrone
,3956050,half-life,The mean antipyrine half-life in the 5 long term users of injectable progestagen was 14.21 +/- 2.53 hours compared with 13.66 +/- 0.98 hours in non-users.,Salivary antipyrine half-life during injectable progestagen contraception. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3956050/),h,13.66,61634,DB00717,Norethindrone
,428229,terminal elimination half lives,"After the peak, NE plasma levels declined in two phases, with a mean terminal elimination half lives of 4 to 6.9h.",Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/428229/),h,4 to 6.9,65808,DB00717,Norethindrone
,639831,plasma half-life,The plasma half-life was about 5 h in both sexes with single oral doses of 5 to 20 mg.,Bioavailability of norethindrone in human subjects. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/639831/),h,5,66554,DB00717,Norethindrone
,119608,clearance half-lives,The clearance half-lives were 1.3 hours for 'alpha' and 10.0 hours for 'beta'.,The rabbit as an animal model to study pharmacokinetics of norethindrone in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119608/),h,1.3,67141,DB00717,Norethindrone
,119608,clearance half-lives,The clearance half-lives were 1.3 hours for 'alpha' and 10.0 hours for 'beta'.,The rabbit as an animal model to study pharmacokinetics of norethindrone in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119608/),h,10.0,67142,DB00717,Norethindrone
,119608,beta,The clearance half-lives were 1.3 hours for 'alpha' and 10.0 hours for 'beta'.,The rabbit as an animal model to study pharmacokinetics of norethindrone in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/119608/),h,10.0,67143,DB00717,Norethindrone
,119608,t 1/2,"In monkeys, plasma NET values showed an inconsistent pattern and the approximate t 1/2 was found to lie between 4 and 6 hours.",The rabbit as an animal model to study pharmacokinetics of norethindrone in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/119608/),h,4 and 6,67144,DB00717,Norethindrone
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],3.6,71125,DB00717,Norethindrone
,6786829,peak,Plasma concentrations of Ng rise to a peak of 3.6 ng/ml after an oral dose of 150 microgram and to 5.0 ng/ml after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[ng] / [ml],5.0,71126,DB00717,Norethindrone
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,0.76,71127,DB00717,Norethindrone
,6786829,half-lives,"Following the intravenous administration of Ng, plasma concentrations of the steroid decline bi-exponentially with mean half-lives of 0.76 and 11.55 hours.",The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),h,11.55,71128,DB00717,Norethindrone
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,89,71129,DB00717,Norethindrone
,6786829,systemic bioavailability,Comparison of the results of the intravenous and oral administration of the steroid show a mean systemic bioavailability of 89% after the 150 microgram dose and 99% after a 250 microgram dose.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),%,99,71130,DB00717,Norethindrone
,6786829,peak values,The peak values after oral dosing were 103 pg/ml and were reached by 1.0 hour in all subjects.,The pharmacokinetics of levonorgestrel and ethynylestradiol in women - studies with Ovran and Ovranette. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6786829/),[pg] / [ml],103,71131,DB00717,Norethindrone
,7445531,half-life,"5. Rifampicin treatment (7.5 mg/kg/day, orally) for 8 days decreased the half-life of total 14C in plasma following a single oral dose of 4-[14C]ethynodiol diacetate (0.15 mg/kg) from 44 +/- to 24 +/- 2 h.",Metabolism of ethynodiol diacetate in the rhesus monkey before and after administration of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445531/),h,44,77342,DB00717,Norethindrone
,7445531,half-life,"5. Rifampicin treatment (7.5 mg/kg/day, orally) for 8 days decreased the half-life of total 14C in plasma following a single oral dose of 4-[14C]ethynodiol diacetate (0.15 mg/kg) from 44 +/- to 24 +/- 2 h.",Metabolism of ethynodiol diacetate in the rhesus monkey before and after administration of rifampicin. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7445531/),h,24,77343,DB00717,Norethindrone
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],8.2,91245,DB00717,Norethindrone
,14663455,oral clearance,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],9.5,91246,DB00717,Norethindrone
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,23.4,91247,DB00717,Norethindrone
,14663455,half-life,"Concomitant use of St John's wort was associated with a significant (P <.05) increase in the oral clearance of norethindrone (8.2 +/- 2.7 L/h to 9.5 +/- 3.4 L/h, P =.042) and a significant reduction in the half-life of ethinyl estradiol (23.4 +/- 19.5 hours to 12.2 +/- 7.1 hours, P =.023).",The interaction between St John's wort and an oral contraceptive. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),h,12.2,91248,DB00717,Norethindrone
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],109.2,91249,DB00717,Norethindrone
,14663455,oral clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],166.7,91250,DB00717,Norethindrone
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],37.7,91251,DB00717,Norethindrone
,14663455,systemic clearance,"The oral clearance of midazolam was significantly increased (109.2 +/- 47.9 L/h to 166.7 +/- 81.3 L/h, P =.007) during St John's wort administration, but the systemic clearance of midazolam was unchanged (37.7 +/- 11.3 L/h to 39.0 +/- 10.3 L/h, P =.567).",The interaction between St John's wort and an oral contraceptive. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],39.0,91252,DB00717,Norethindrone
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],215.9,91253,DB00717,Norethindrone
,14663455,oral clearance,The oral clearance of midazolam after St John's wort dosing was greater in women who had breakthrough bleeding (215.9 +/- 66.5 L/h) than in those who did not (97.5 +/- 37.2 L/h) (P =.005).,The interaction between St John's wort and an oral contraceptive. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14663455/),[l] / [h],97.5,91254,DB00717,Norethindrone
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.3,94875,DB00717,Norethindrone
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,27.7,94876,DB00717,Norethindrone
,7059433,elimination half-life,"The elimination half-life was 27.3 +/- 1.3 h in males, 27.7 +/- 1.5 h in females in the follicular phase and 29.6 +/- 1.4 h in the luteal phase of the menstrual cycle.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,29.6,94877,DB00717,Norethindrone
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],59.3,94878,DB00717,Norethindrone
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],58.2,94879,DB00717,Norethindrone
,7059433,Total plasma clearance,"Total plasma clearance was 59.3 +/- 2.7 ml/min, 58.2 +/- 3.3 and 55.8 +/- 5.0 ml/min respectively.","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],55.8,94880,DB00717,Norethindrone
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,30.6,94881,DB00717,Norethindrone
,7059433,elimination half-life,3 The use of OC-steroids did not significantly alter the elimination half-life of nitrazepam: 30.6 +/- 2.3 and 31.2 +/- 2.2 h in the first and second half of the pill cycle.,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),h,31.2,94882,DB00717,Norethindrone
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],46.6,94883,DB00717,Norethindrone
,7059433,total nitrazepam clearance,The total nitrazepam clearance in these females (46.6 +/- 4.6 and 45.6 +/- 4.1 ml/min) was significantly lower than in males (P less than 0.05).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],45.6,94884,DB00717,Norethindrone
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,11.4,94885,DB00717,Norethindrone
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,12.4,94886,DB00717,Norethindrone
,7059433,protein unbound fraction,The protein unbound fraction of nitrazepam was progressively higher going from males (11.4 +/- 0.1%) to females in the luteal phase of the cycle (12.4 +/- 0.5%) to females using OC-steroids (13.5 +/- 0.4%).,"Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),%,13.5,94887,DB00717,Norethindrone
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],323,94888,DB00717,Norethindrone
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],530,94889,DB00717,Norethindrone
,7059433,Cli,"The clearance calculated relative to the unbound drug (intrinsic clearance) was significantly decreased in females taking OC-steroids as compared to males and females not taking them (Cli = 323 +/- 30 ml/min in females using OC-steroids, 530 +/- 37 ml/min in males and 459 +/- 40 ml/min in females).","Influence of sex, menstrual cycle and oral contraception on the disposition of nitrazepam. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7059433/),[ml] / [min],459,94890,DB00717,Norethindrone
,2620531,time required to reach maximum plasma concentration (Tmax),"The time required to reach maximum plasma concentration (Tmax) became shorter with decreasing particle size, 1.69 hr, 1.52 hr and 1.06 hr, respectively.",Pharmacokinetics of norethindrone: effect of particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),h,1.69,96615,DB00717,Norethindrone
,2620531,time required to reach maximum plasma concentration (Tmax),"The time required to reach maximum plasma concentration (Tmax) became shorter with decreasing particle size, 1.69 hr, 1.52 hr and 1.06 hr, respectively.",Pharmacokinetics of norethindrone: effect of particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),h,1.52,96616,DB00717,Norethindrone
,2620531,time required to reach maximum plasma concentration (Tmax),"The time required to reach maximum plasma concentration (Tmax) became shorter with decreasing particle size, 1.69 hr, 1.52 hr and 1.06 hr, respectively.",Pharmacokinetics of norethindrone: effect of particle size. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),h,1.06,96617,DB00717,Norethindrone
,2620531,maximum NET plasma concentration (Cmax),"As particle size was reduced, the maximum NET plasma concentration (Cmax) increased for the 3 different 1 mg NET preparations, i.e. 8.66 ng/ml, 10.53 ng/ml and 15.73 ng/ml.",Pharmacokinetics of norethindrone: effect of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),[ng] / [ml],8.66,96618,DB00717,Norethindrone
,2620531,maximum NET plasma concentration (Cmax),"As particle size was reduced, the maximum NET plasma concentration (Cmax) increased for the 3 different 1 mg NET preparations, i.e. 8.66 ng/ml, 10.53 ng/ml and 15.73 ng/ml.",Pharmacokinetics of norethindrone: effect of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),[ng] / [ml],10.53,96619,DB00717,Norethindrone
,2620531,maximum NET plasma concentration (Cmax),"As particle size was reduced, the maximum NET plasma concentration (Cmax) increased for the 3 different 1 mg NET preparations, i.e. 8.66 ng/ml, 10.53 ng/ml and 15.73 ng/ml.",Pharmacokinetics of norethindrone: effect of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),[ng] / [ml],15.73,96620,DB00717,Norethindrone
,2620531,Cmax,A trial with a 2 mg NET preparation made with NET utilizing the 44 microns same material displayed a Tmax similar to the 1 mg NET preparation having the same particle size while the Cmax reached a level of 17.56 ng/ml.,Pharmacokinetics of norethindrone: effect of particle size. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2620531/),[ng] / [ml],17.56,96621,DB00717,Norethindrone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.4,100284,DB00717,Norethindrone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],10.5,100285,DB00717,Norethindrone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],420.6,100286,DB00717,Norethindrone
,18061638,EC50,"Dienogest activate PR (EC50=3.4 or 10.5 nmol/l) with antagonistic activity on AR (EC50=420.6 or 775.0 nmol/l) but not agonistic nor antagonistic action on GR, MR (3000 nmol/l).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],775.0,100287,DB00717,Norethindrone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.0042,100288,DB00717,Norethindrone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.074,100289,DB00717,Norethindrone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],1.9,100290,DB00717,Norethindrone
,18061638,ED50,"By oral treatment, dienogest showed the strongest endometrial activity (ED50=0.0042 mg/kg) in McPhail test among other progestins (ED50 values for MPA, DYG, NES were 0.074, 1.9, >0.05 mg/kg, respectively).",Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[mg] / [kg],0.05,100291,DB00717,Norethindrone
,18061638,ED50,The estimated plasma concentration of dienogest at ED50 (3.66 nmol/l) was close to its EC50 value to activate PR.,Dienogest is a selective progesterone receptor agonist in transactivation analysis with potent oral endometrial activity due to its efficient pharmacokinetic profile. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18061638/),[nM] / [l],3.66,100292,DB00717,Norethindrone
,484634,half-life,The disappearance curve due to norethindrone acetate showed an initial rapid disappearance of 3H with an average half-life of 7.5 minutes and a subsequent slow disapperance with a half-life of 51.5 hours.,Pharmacokinetics of norethindrone acetate in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/484634/),min,7.5,107299,DB00717,Norethindrone
,484634,half-life,The disappearance curve due to norethindrone acetate showed an initial rapid disappearance of 3H with an average half-life of 7.5 minutes and a subsequent slow disapperance with a half-life of 51.5 hours.,Pharmacokinetics of norethindrone acetate in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/484634/),h,51.5,107300,DB00717,Norethindrone
,484634,MCR,Norethindrone acetate was cleared from the plasma with an average MCR of 495 L/day.,Pharmacokinetics of norethindrone acetate in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/484634/),[l] / [d],495,107301,DB00717,Norethindrone
,484634,half-life,"Norethindrone, the main metabolite, disappears from the plasma with an average half-life of 34.8 hours.",Pharmacokinetics of norethindrone acetate in women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/484634/),h,34.8,107302,DB00717,Norethindrone
,1816419,t 1/2 ka,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.21,109947,DB00717,Norethindrone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,1.28,109948,DB00717,Norethindrone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.37,109949,DB00717,Norethindrone
,1816419,t 1/2 alpha,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,0.90,109950,DB00717,Norethindrone
,1816419,t 1/2 beta,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,10.01,109951,DB00717,Norethindrone
,1816419,t 1/2 beta,"Average t 1/2 ka, t 1/2 alpha and t 1/2 beta with standard deviation for oral administration were 0.21 +/- 0.08 (h), 1.28 +/- 0.31 (h) and 10.01 +/- 4.59 (h) for NET and 0.37 +/- 0.81 (h), 0.90 +/- 0.26 (h) and 8.55 +/- 2.21 (h) for NETO respectively.",Pharmacokinetic studies of norethisterone-3-oxime and norethisterone-3-oxime acetate in rhesus monkey. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1816419/),h,8.55,109952,DB00717,Norethindrone
,7319102,peak concentration,"After the administration of norethindrone, the peak level of norethindrone in the plasma was obtained within 2h, and the peak concentration in the plasma was about 3.5 ng/ml/mg norethindrone.",[Pharmacokinetics of norethindrone and lynestrenol studied by HPLC (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319102/),[ng] / [mg·ml],3.5,117018,DB00717,Norethindrone
,7319102,half life,"During a period of 2-6hs after the administration of norethindrone, the half life of norethindrone in the plasma was approximately 1.8h, and during the period of 6-24hs, half life was variable.",[Pharmacokinetics of norethindrone and lynestrenol studied by HPLC (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319102/),h,1.8,117019,DB00717,Norethindrone
,7319102,peak concentration,"On the other hand, after the administration of lynestrenol, the peak level of norethindrone in the plasma was obtained within 4h, and the peak concentration of norethindrone was about 1.9 ng/ml/mg lynestrenol.",[Pharmacokinetics of norethindrone and lynestrenol studied by HPLC (author's transl)]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319102/),[ng] / [lynestrenol·mg·ml],1.9,117020,DB00717,Norethindrone
,7319102,half life,"During a period of 4-12hs, the half life of norethindrone was about 2.5h.",[Pharmacokinetics of norethindrone and lynestrenol studied by HPLC (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7319102/),h,2.5,117021,DB00717,Norethindrone
,30617756,zeta potentials,"Mean diameters of PECs were 183-425 nm, mean zeta potentials were + 18.6-+ 31 mV, and complexation efficiencies were 18.0-20.6%.",Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617756/),mv,18,124233,DB00717,Norethindrone
,30617756,zeta potentials,"Mean diameters of PECs were 183-425 nm, mean zeta potentials were + 18.6-+ 31 mV, and complexation efficiencies were 18.0-20.6%.",Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617756/),mv,31,124234,DB00717,Norethindrone
,30617756,zeta potential,"Mean diameter of LMF 2 was 10.5 ± 0.57 nm, mean zeta potential was - 11.07 ± - 0.49 mV, encapsulation efficiency was 95.28 ± 1.75%, and each mL contained 145.5 μg norethindrone.",Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617756/),mv,-,124235,DB00717,Norethindrone
,30617756,zeta potential,"Mean diameter of LMF 2 was 10.5 ± 0.57 nm, mean zeta potential was - 11.07 ± - 0.49 mV, encapsulation efficiency was 95.28 ± 1.75%, and each mL contained 145.5 μg norethindrone.",Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617756/),mv,11.07,124236,DB00717,Norethindrone
,30617756,encapsulation efficiency,"Mean diameter of LMF 2 was 10.5 ± 0.57 nm, mean zeta potential was - 11.07 ± - 0.49 mV, encapsulation efficiency was 95.28 ± 1.75%, and each mL contained 145.5 μg norethindrone.",Preparation and Characterization of an Oral Norethindrone Sustained Release/Controlled Release Nanoparticles Formulation Based on Chitosan. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30617756/),%,95.28,124237,DB00717,Norethindrone
,3621943,t1/2,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),h,7.6,126883,DB00717,Norethindrone
,3621943,bioavailability,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[ng] / [h·ml],53.6,126884,DB00717,Norethindrone
,3621943,C max,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[ng] / [ml],4.63,126885,DB00717,Norethindrone
,3621943,clearance,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),[l] / [h],22.6,126886,DB00717,Norethindrone
,3621943,Vd,"Mean values for the parameters were t1/2, 7.6 h; bioavailability, 53.6 ng/ml/h; C max, 4.63 ng/ml; clearance, 22.6 l/h; and Vd 2361.",Pharmacokinetics of norethisterone in humans. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3621943/),,2361,126887,DB00717,Norethindrone
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1139,127782,DB00717,Norethindrone
,15823769,AUC over a 24-hour dosing interval (AUC(tau)),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·pg] / [ml],1143,127783,DB00717,Norethindrone
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],133,127784,DB00717,Norethindrone
,15823769,C(max),"For EE, the mean (SD) AUC over a 24-hour dosing interval (AUC(tau)) was 1139 (317) pg.h/mL in cycle 2 and 1143 (312) pg.h/mL in cycle 3; the mean C(max) in the respective cycles was 133 (39) and 141 (46) pg/mL.",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[pg] / [ml],141,127785,DB00717,Norethindrone
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],140,127786,DB00717,Norethindrone
,15823769,AUC(tau),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[h·ng] / [ml],159,127787,DB00717,Norethindrone
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],21,127788,DB00717,Norethindrone
,15823769,C(max),"For NOR, the corresponding values were 140 (48) and 159 (46) ng.h/mL for AUC(tau) and 21 (5.4) and 23 (6.7) ng/mL for C(max).",Effect of zonisamide on the pharmacokinetics and pharmacodynamics of a combination ethinyl estradiol-norethindrone oral contraceptive in healthy women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15823769/),[ng] / [ml],23,127789,DB00717,Norethindrone
,22365683,flow rate,The flow rate was 0.500 mL min(-1).,Simple and rapid determination of norethindrone in human plasma by supported liquid extraction and ultra performance liquid chromatography with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22365683/),[ml] / [min],0.500,140453,DB00717,Norethindrone
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,4.9,141771,DB00717,Norethindrone
,2058339,t1/2,"Deposiston was found markedly delay the elimination half-life life of caffeine (p less than 0.05): t1/2 prior to therapy 4.9 +/- 2.6 h and, after as little as 2 mg ethinylestradiol sulphonate 8.0 +/- 3.5 h.",[Time course of inhibition of caffeine elimination in response to the oral depot contraceptive agent Deposiston. Hormonal contraceptives and caffeine elimination]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2058339/),h,8.0,141772,DB00717,Norethindrone
,17707721,flow rate,"Separation was carried out on a C(18) column maintained at 20 degrees C with acetonitrile-water (80:20, v/v) as mobile phase at a flow rate of 0.6 mL/min.",Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17707721/),[ml] / [min],0.6,143431,DB00717,Norethindrone
,17707721,limit of detection,The limit of detection for the assay was 3 ng/mL.,Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17707721/),[ng] / [ml],3,143432,DB00717,Norethindrone
,17707721,absolute recovery,The absolute recovery was 91.7-100.1%.,Development of a high-performance liquid chromatographic method for the determination of mifepristone in human plasma using norethisterone as an internal standard: application to pharmacokinetic study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17707721/),%,91.7-100.1,143433,DB00717,Norethindrone
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),nM,2.9,148043,DB00717,Norethindrone
,4028723,maximum level,The (geometric) mean maximum level of MPA was 2.9 (2.4-3.7) nmol/1 and that of NET 10.1 (6.4-15.8) nmol/l.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[nM] / [l],10.1,148044,DB00717,Norethindrone
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],890,148045,DB00717,Norethindrone
,4028723,maximum level,The maximum level of exogenous E2 was 890 (700-1130) pmol/l after Cycloprovera and 1570 (870-2820) pmol/l after HRP-102 administration.,Pharmacokinetic and pharmacodynamic investigations with monthly injectable contraceptive preparations. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4028723/),[pM] / [l],1570,148046,DB00717,Norethindrone
,11204938,tmax,Identical median tmax was observed for E2 (6 h) and for E1 (5 h).,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,6,150801,DB00717,Norethindrone
,11204938,tmax,Identical median tmax was observed for E2 (6 h) and for E1 (5 h).,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,5,150802,DB00717,Norethindrone
,11204938,tmax,The median tmax for Novofem was 0.75 h and for Trisequens 1.0 h.,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,0.75,150803,DB00717,Norethindrone
,11204938,tmax,The median tmax for Novofem was 0.75 h and for Trisequens 1.0 h.,Bioequivalence and relative bioavailability of three estradiol and norethisterone acetate-containing hormone replacement therapy tablets. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11204938/),h,1.0,150804,DB00717,Norethindrone
,20842042,AUC0-168 h,Patch EE median AUC0-168 h was 45% lower at 6010.36 pg·h·mL in those on LPV/r versus 10911.42 pg·h·mL in those on no HAART (P = 0.064).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,6010.36,171328,DB00717,Norethindrone
,20842042,AUC0-168 h,Patch EE median AUC0-168 h was 45% lower at 6010.36 pg·h·mL in those on LPV/r versus 10911.42 pg·h·mL in those on no HAART (P = 0.064).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,10911.42,171329,DB00717,Norethindrone
,20842042,AUC0-48 hours,Pill EE median AUC0-48 hours was similarly 55% lower at 344.67 pg·h·mL in those on LPV/r versus 765.38 pg·h·mL in those on no HAART (P = 0.003).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,344.67,171330,DB00717,Norethindrone
,20842042,AUC0-48 hours,Pill EE median AUC0-48 hours was similarly 55% lower at 344.67 pg·h·mL in those on LPV/r versus 765.38 pg·h·mL in those on no HAART (P = 0.003).,Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·pg,765.38,171331,DB00717,Norethindrone
,20842042,AUC0-168 h,"Patch NGMN AUC0-168 h however, was 138.39 ng·h·mL, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL (P = 0.036).",Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·ng,138.39,171332,DB00717,Norethindrone
,20842042,AUC,"Patch NGMN AUC0-168 h however, was 138.39 ng·h·mL, 83% higher in the LPV/r group compared with the control AUC of 75.63 ng·h·mL (P = 0.036).",Contraceptive efficacy of oral and transdermal hormones when co-administered with protease inhibitors in HIV-1-infected women: pharmacokinetic results of ACTG trial A5188. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20842042/),h·ml·ng,75.63,171333,DB00717,Norethindrone
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.5,171434,DB00717,Norethindrone
,1301358,urinary to fecal excretion ratio,A urinary to fecal excretion ratio of 1.5 (i.v.) or 1.0 (i.g.) was found.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",fe-Q44,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,1.0,171435,DB00717,Norethindrone
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,0.8,171436,DB00717,Norethindrone
,1301358,half-life,Renal excretion of total radiolabel proceeded with a half-life of about 0.8 (i.v.) or 1.1 (i.g.) days.,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),d,1.1,171437,DB00717,Norethindrone
,1301358,total clearance,Orally administered NETO was highly bioavailable (84.0 +/- 16.9% of dose) but rapidly cleared from plasma (total clearance corresponded to 97% of plasma liver flow).,"Pharmacokinetics, hydrolysis and aromatisation of norethisterone-3-oxime in female cynomolgus monkey. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1301358/),,97,171438,DB00717,Norethindrone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1126,176226,DB00717,Norethindrone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·pg] / [ml],1208,176227,DB00717,Norethindrone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],178,176228,DB00717,Norethindrone
,11402638,AUC(0-24),"For RSG + OC and P + OC, respectively, mean ethinylestradiol AUC(0-24) was 1126 and 1208 pg.h/mL (PE: 0.92; 90% CI: 0.88-0.97), and mean norethindrone AUC(0-24) was 178 and 171 ng.h/mL (PE: 1.04; 90% CI: 1.00-1.07).",Lack of effect of rosiglitazone on the pharmacokinetics of oral contraceptives in healthy female volunteers. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11402638/),[h·ng] / [ml],171,176229,DB00717,Norethindrone
below,1936077,t1/2,"Rat hepatocytes showed an extremely high metabolic activity towards NET, LN and GEST resulting in t1/2 values of below 2 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,2,181047,DB00717,Norethindrone
above,1936077,half-lives,"Respective values for rabbit hepatocytes ranged from 5-8 min, whereas half-lives calculated for liver cells from guinea pig, dog and monkey were generally above 30 min.",Investigations on the in vitro metabolism of five synthetic 19-norprogestins using hepatocyte suspensions isolated from five laboratory animal species. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1936077/),min,30,181048,DB00717,Norethindrone
,29522253,maximum oral equivalent dose,"The maximum oral equivalent dose of ethinylestradiol was markedly lower than 30 μg ethinylestradiol per day (20.3 μg/day; 90% confidence interval, 14.8-28.0 μg/day).",In Vivo Formation of Ethinylestradiol After Intramuscular Administration of Norethisterone Enantate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29522253/),[μg] / [d],20.3,183130,DB00717,Norethindrone
,2278844,Ka,"The antiserum, raised against 7 alpha-methyl-19-nortestosterone-3-O-oxime-bovine serum albumin, had a low titer (final dilution = 1:4500) and low affinity (Ka = 1.17 x 10(9) l/mol) but showed little or no cross-reactivity with several of the steroids tested.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [mol],1.17 x 10(9),183725,DB00717,Norethindrone
,2278844,sensitivity,The sensitivity of the RIA was 28.2 pg/ml and the mean recovery of added cold steroid was 86 to 100%.,Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[pg] / [ml],28.2,183726,DB00717,Norethindrone
,2278844,metabolic clearance rates (MCR),"The metabolic clearance rates (MCR) of 7MENT as determined from the plasma disappearance curve for rats and rabbits were 50 l/day and 336 l/day, respectively.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [d],50,183727,DB00717,Norethindrone
,2278844,metabolic clearance rates (MCR),"The metabolic clearance rates (MCR) of 7MENT as determined from the plasma disappearance curve for rats and rabbits were 50 l/day and 336 l/day, respectively.",Radioimmunoassay of 7 alpha-methyl-19-nortestosterone and investigation of its pharmacokinetics in animals. ,CLint-Q29,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2278844/),[l] / [d],336,183728,DB00717,Norethindrone
,6990558,maximum,The maximum values achieved in saliva (775--1430 pmol/l) were only approximately 3% of those observed in plama.,A sensitive solid phase enzymeimmunoassay for norethisterone (norethindrone) in saliva and plasma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6990558/),[pM] / [l],775,185391,DB00717,Norethindrone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],96,188806,DB00717,Norethindrone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],205,188807,DB00717,Norethindrone
,6833459,Plasma clearance,"Plasma clearance of total prednisolone in females on OC was 96 +/- 9 (SD) ml/min X 1.73 m2, significantly (P less than 0.001) lower than those in both male and female controls (205 +/- 46 and 187 +/- 22 ml/min X 1.73 m2).",Prednisolone disposition and protein binding in oral contraceptive users. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6833459/),[ml] / [1.73·m2·min],187,188808,DB00717,Norethindrone
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191767,DB00717,Norethindrone
,4042465,distribution volume,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[l] / [kg],0.44,191768,DB00717,Norethindrone
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191769,DB00717,Norethindrone
,4042465,total body clearance,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),[ml] / [kg·min],0.78,191770,DB00717,Norethindrone
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,402,191771,DB00717,Norethindrone
,4042465,elimination T 1/2,"The distribution volume (0.44 +/- 0.06 L/kg in control vs. 0.44 +/- 0.09 L/kg oral contraceptive group), total body clearance (0.78 +/- 0.13 ml/kg/min vs 0.78 +/- 0.18 ml/kg/min) and elimination T 1/2 (402 +/- 78 min vs. 409 +/- 126 min) were identical in the two groups.",Theophylline pharmacokinetics in adolescent females following coadministration of oral contraceptives. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/4042465/),min,409,191772,DB00717,Norethindrone
,3909274,volume of distribution (Vdarea),At three days post irradiation there was an increase in volume of distribution (Vdarea) from 5.55 +/- 0.93 l/kg for sham irradiated to 11.28 +/- 0.74 l/kg for 600 rad rats.,Norethindrone disposition following x-ionizing radiation in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),[l] / [kg],5.55,199584,DB00717,Norethindrone
,3909274,volume of distribution (Vdarea),At three days post irradiation there was an increase in volume of distribution (Vdarea) from 5.55 +/- 0.93 l/kg for sham irradiated to 11.28 +/- 0.74 l/kg for 600 rad rats.,Norethindrone disposition following x-ionizing radiation in rats. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),[l] / [kg],11.28,199585,DB00717,Norethindrone
,3909274,Half-life,Half-life increased after exposure to x-rays from 45.2 +/- 4.5 minutes for sham irradiated to 85.5 +/- 12.1 minutes for 600 rads dose.,Norethindrone disposition following x-ionizing radiation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),min,45.2,199586,DB00717,Norethindrone
,3909274,Half-life,Half-life increased after exposure to x-rays from 45.2 +/- 4.5 minutes for sham irradiated to 85.5 +/- 12.1 minutes for 600 rads dose.,Norethindrone disposition following x-ionizing radiation in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),min,85.5,199587,DB00717,Norethindrone
,3909274,Mean Residence Time (MRT),The Mean Residence Time (MRT) increased from 56.7 +/- 5.6 minutes to 96.4 +/- 13.6 minutes after exposure to 600 rads.,Norethindrone disposition following x-ionizing radiation in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),min,56.7,199588,DB00717,Norethindrone
,3909274,Mean Residence Time (MRT),The Mean Residence Time (MRT) increased from 56.7 +/- 5.6 minutes to 96.4 +/- 13.6 minutes after exposure to 600 rads.,Norethindrone disposition following x-ionizing radiation in rats. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3909274/),min,96.4,199589,DB00717,Norethindrone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],459,201305,DB00717,Norethindrone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],489,201306,DB00717,Norethindrone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],522,201307,DB00717,Norethindrone
,7058686,MCR,"No significant change in the MCR of NETA was observed at 1 week (459 +/- 72 1/day), 1 month (489 +/- 113 1/day) and 2 months (522 +/- 144 1/day) compared with that of control (525 +/- 108 1/day).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],525,201308,DB00717,Norethindrone
,7058686,MCR,"However, MCR of NETA showed significant increase in women exposed to continuous presence of NETA for a period of 6 months (608 +/- 121 1/day; P less than 0.025).",Pharmacokinetics of norethindrone acetate in women after the insertion of a single subdermal implant releasing norethindrone acetate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7058686/),[1] / [d],608,201309,DB00717,Norethindrone
,7273765,half-life of absorption,The half-life of absorption varied from 5.4 to 22.3 days and the half-life of elimination varied from 7.5 to 22.5 days; there was a significant correlation (R = 0.78) between these two half-lives.,Pharmacokinetics of norethisterone oenanthate in humans. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273765/),d,5.4 to 22.3,203537,DB00717,Norethindrone
,7273765,half-life of elimination,The half-life of absorption varied from 5.4 to 22.3 days and the half-life of elimination varied from 7.5 to 22.5 days; there was a significant correlation (R = 0.78) between these two half-lives.,Pharmacokinetics of norethisterone oenanthate in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7273765/),d,7.5 to 22.5,203538,DB00717,Norethindrone
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1014,214896,DB00717,Norethindrone
,7189454,area under the plasma EE versus time curve,The area under the plasma EE versus time curve increased significantly on stopping rifampicin from 1014 +/- 317 pg/ml x h (mean +/- SE) to 1747 +/- 218 pg/ml x h (p less than 0.01).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),[pg] / [h·ml],1747,214897,DB00717,Norethindrone
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,2.9,214898,DB00717,Norethindrone
,7189454,terminal plasma half-life,The terminal plasma half-life increased from 2.9 +/- 0.8 h to 6.3 +/- 1.4 h (p less than 0.005).,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),h,6.3,214899,DB00717,Norethindrone
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,213.4,214900,DB00717,Norethindrone
,7189454,capacity,The sex hormone binding globulin (S.H.B.G.) capacity was also reduced from 213.4 +/- 11.5 nmoles to 129.0 +/- 7.7 nmoles/1 after stopping rifampicin.,The effect of rifampicin on the pharmacokinetics of ethynylestradiol in women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7189454/),nmoles,129.0,214901,DB00717,Norethindrone
,16550733,Cmax,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[ng] / [ml],9.8,229682,DB00717,Norethindrone
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·ng] / [ml],72.9,229683,DB00717,Norethindrone
,16550733,AUC0-infinity,"In the absence of bosentan, the pharmacokinetics of norethisterone and ethinyl estradiol were characterized by Cmax and AUC0-infinity values (95% CI) of 9.8 (8.1, 11.9) ng/ml and 72.9 (57.0, 93.1) ng x h/ml, and 53.0 (47.0, 59.9) pg/ml and 758 (655, 878) pg x h/ml, respectively.",Pharmacokinetic interaction between bosentan and the oral contraceptives norethisterone and ethinyl estradiol. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16550733/),[h·pg] / [ml],758,229684,DB00717,Norethindrone
,16213451,flow rate,The flow rate was 1.0 ml/min and the total run time was 5.0 min.,Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry--experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213451/),[ml] / [min],1.0,230396,DB00717,Norethindrone
,16213451,total run time,The flow rate was 1.0 ml/min and the total run time was 5.0 min.,Simultaneous determination of norethindrone and ethinyl estradiol in human plasma by high performance liquid chromatography with tandem mass spectrometry--experiences on developing a highly selective method using derivatization reagent for enhancing sensitivity. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16213451/),min,5.0,230397,DB00717,Norethindrone
,509953,half-lives,"Following the intravenous administration of the same dose of EE, plasma concentrations of the steroid declined biexponentially, the two half-lives being 0.83 and 6.75 hours.",An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),h,0.83,230597,DB00717,Norethindrone
,509953,half-lives,"Following the intravenous administration of the same dose of EE, plasma concentrations of the steroid declined biexponentially, the two half-lives being 0.83 and 6.75 hours.",An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),h,6.75,230598,DB00717,Norethindrone
,509953,oral bioavailability,Comparison of the results of the intravenous and oral administration of the steroid suggested that its oral bioavailability is 42%.,An investigation of the pharmacokinetics of ethynylestradiol in women using radioimmunoassay. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/509953/),%,42,230599,DB00717,Norethindrone
,436304,plasma half life,The plasma half life of Net after NET and lyn administration for the period 8-24 h was 8-11 h.,Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436304/),h,8-11,236950,DB00717,Norethindrone
,436304,plasma half life,"When 5 mg NET was given the plasma half life of NET for the period 24-72 h was around 10 h and this was significantly shorter than the half-life of NET after 5 mg lyn, which was 16 1/2 h.",Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436304/),h,10,236951,DB00717,Norethindrone
,436304,half-life,"When 5 mg NET was given the plasma half life of NET for the period 24-72 h was around 10 h and this was significantly shorter than the half-life of NET after 5 mg lyn, which was 16 1/2 h.",Plasma levels of norethindrone after single oral dose administration of norethindrone and lynestrenol. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/436304/),h,16 1/2,236952,DB00717,Norethindrone
,2737742,peak plasma levels,In the women taking 1 mg NET-acetate containing pills peak plasma levels ranging from 6.2 to 20.8 ng/ml were observed at 1 hr whereas with 500 micrograms pill they ranged from 2.0 to 6.5 ng/ml and the peak was noted at 4 hr.,Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737742/),[ng] / [ml],6.2 to 20.8,237231,DB00717,Norethindrone
,2737742,peak plasma levels,In the women taking 1 mg NET-acetate containing pills peak plasma levels ranging from 6.2 to 20.8 ng/ml were observed at 1 hr whereas with 500 micrograms pill they ranged from 2.0 to 6.5 ng/ml and the peak was noted at 4 hr.,Pharmacokinetics of norethisterone from two different combination contraceptive pills in Indian women. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2737742/),[ng] / [ml],2.0 to 6.5,237232,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pg] / [ml],595,243947,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pM] / [l],"2,184",243948,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pg] / [ml],435,243949,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pM] / [l],"1,597",243950,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pg] / [ml],712,243951,DB00717,Norethindrone
,7959337,peak estradiol concentrations,"The mean peak estradiol concentrations were noted 2 h after drug administration and amounted to 595 +/- 190 pg/ml (2,184 +/- 697 pmol/l) in the entire cohort; 435 +/- 117 pg/ml (1,597 +/- 430 pmol/l) in group A and 712 +/- 142 pg/ml (2,614 +/- 521 pmol/l) in group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pM] / [l],"2,614",243952,DB00717,Norethindrone
,7959337,total area under the curve,"The mean total area under the curve in group A was 4,887 pg/ml (17,940 pmol/l), which was significantly lower than that of 7,995 +/- 652 pg/ml/24 h (29,350 +/- 2,393 pmol/l/24 h) found for group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pg] / [ml],"4,887",243953,DB00717,Norethindrone
,7959337,total area under the curve,"The mean total area under the curve in group A was 4,887 pg/ml (17,940 pmol/l), which was significantly lower than that of 7,995 +/- 652 pg/ml/24 h (29,350 +/- 2,393 pmol/l/24 h) found for group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pM] / [l],"17,940",243954,DB00717,Norethindrone
,7959337,total area under the curve,"The mean total area under the curve in group A was 4,887 pg/ml (17,940 pmol/l), which was significantly lower than that of 7,995 +/- 652 pg/ml/24 h (29,350 +/- 2,393 pmol/l/24 h) found for group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pg] / [24·h·ml],"7,995",243955,DB00717,Norethindrone
,7959337,total area under the curve,"The mean total area under the curve in group A was 4,887 pg/ml (17,940 pmol/l), which was significantly lower than that of 7,995 +/- 652 pg/ml/24 h (29,350 +/- 2,393 pmol/l/24 h) found for group B (p < 0.001).",Estrogen replacement in postmenopausal women: are we currently overdosing our patients? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7959337/),[pM] / [24·h·l],"29,350",243956,DB00717,Norethindrone
,3665485,area under the plasma norethindrone versus time curve,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),[ng] / [h·ml],0.72,252326,DB00717,Norethindrone
,3665485,area under the plasma norethindrone versus time curve,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),[ng] / [h·ml],0.49,252327,DB00717,Norethindrone
,3665485,oral bioavailability,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),%,56,252328,DB00717,Norethindrone
,3665485,oral bioavailability,"However, after oral administration of norethindrone, the area under the plasma norethindrone versus time curve was significantly decreased by aspirin from 0.72 +/- 0.058 ng/ml X hr to 0.49 +/- 0.046 ng/ml X hr (mean +/- S.E) and the oral bioavailability was reduced from 56 +/- 4.2% to 38 +/- 3.6%, perhaps due to increased gut wall metabolism of norethindrone by aspirin.",Influence of aspirin on the pharmacokinetics of norethindrone. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665485/),%,38,252329,DB00717,Norethindrone
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],6580,269060,DB00717,Norethindrone
,9871424,area under the plasma concentration-time curve (AUC0-infinity),"The mean +/- SD area under the plasma concentration-time curve (AUC0-infinity) for ethinyl estradiol was 6580 +/- 1100 ng.h/L at baseline and 5970 +/- 1560 ng.h/L after the thalidomide regimen (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·ng] / [l],5970,269061,DB00717,Norethindrone
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],41.1,269062,DB00717,Norethindrone
,9871424,AUC0-infinity,"No accumulation of thalidomide was seen after 21 days of therapy: day 1 AUC0-infinity 41.1 +/- 13.9 micrograms.h/mL; day 21 AUC0-infinity 59.6 +/- 27.3 micrograms.h/mL (paired t test, P > .05).",Thalidomide does not alter the pharmacokinetics of ethinyl estradiol and norethindrone. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9871424/),[h·μg] / [ml],59.6,269063,DB00717,Norethindrone
,17258945,run time,"The LC run time is at least 6 min, enabling analysis of only about 100 samples a day.",A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,6,271149,DB00717,Norethindrone
,17258945,run time,In the present work the throughput was greatly improved by employing a semi-automated sample preparation process involving liquid-liquid extraction and derivatization with dansyl chloride followed by UPLC separation on a small particle size column achieving a run time of 2.7 min.,A semi-automated 96-well plate method for the simultaneous determination of oral contraceptives concentrations in human plasma using ultra performance liquid chromatography coupled with tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17258945/),min,2.7,271150,DB00717,Norethindrone
